Protocol Ledger

NCT07252908 · Phase II · COMPLETED

A Phase II Clinical Trial on the Efficacy and Safety of TQC3721 Inhalation Powder

Interventional Phase II clinical trial protocol NCT07252908 sponsored by Chia Tai Tianqing Pharmaceutical Group Co in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-12-22 Enrollment: 195 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT07252908
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)195 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07252908
Protocol FieldVerified Registry Value
NCT IdentifierNCT07252908
Consolidated Lead SponsorChia Tai Tianqing Pharmaceutical Group Co
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase II
Overall Recruitment StatusCOMPLETED
Registered Enrollment195 participants (ACTUAL)
Registered Start Date2025-12-22
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI